Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing resting dyspnea, syncope, or signs and symptoms of acute deterioration, such as cardiac failure, referred to as acute decompensated aortic stenosis (ADAS). As we all know, optimal medical treatment in these cases is limited, with poor prognosis at hospital discharge, 30 days and one year. 

This analysis included 276 patients with ADAS; 150 received TAVR within ≤22 days after hospitalization and the rest, beyond this period. 

The primary outcome was hospitalization for cardiac failure or all-cause mortality.

The groups were comparable: mean patient age 84, 63% men, 53% hypertensive, 35% had coronary artery disease, 5% had PCI within 90 days prior TAVR, 26% had diabetes, 58% kidney function deterioration, 23% COPD and estimated glomerular filtration rate (eGFR) was 55 ml/min. Mean EuroSCORE was 6,5% and 3% required cardiopulmonary support.

Mean ejection fraction was 55%; 15% presented ejection fraction <30%. There were no differences in aortic valve area, gradients, velocity or presence of mitral or tricuspid regurgitation. 40% of patients presented stage >2 deterioration. 

Read also: EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients.

Mean time to TAVR was 14 days in ≤22 day patients and 33 days in the >22 group. 

There were no differences in valve type or hospital evolution. 

Patients were followed up to 4,6 (3,6–5,7) years. The primary outcome was seen in 58% of patients. Time to TAVR (for every 5-day delay) was significantly associated to the primary outcome (hazard ratio [HR], 1,09 [CI 95%, 1,03–1,14]; P=0,002). Also, >22 days to TAVR was associated to higher risk of adverse events (HR 1,48 [CI 95%, 1,09–2,03]; P=0,013).

Read also: Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes.

The was a significant link between the primary outcome and the presence of syncope, COPD, stroke, stage >2 and the need for cardiopulmonary support.

Conclusion

In patients with acute decompensated aortic stenosis, a longer wait to TAVR was associated to increased risk of events at mid-term. 

Original Title: Shorter Time to Transcatheter Aortic Valve Implantation Is Associated With Improved Outcomes in Acute Decompensated Aortic Stenosis.

Reference: Michael McKenna, et al. Circ Cardiovasc Interv. 2025;18:e014915. DOI: 10.1161/CIRCINTERVENTIONS.124.014915.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...